Effect of Tumour Necrosis Factor-Alpha on Estrogen Metabolic Pathways in Breast Cancer Cells

Journal of Cancer

Volumn 3, Issue 1, 2012, Pages 310-321

  Kamel, Marwa ^a   Shouman, Samia ^a   El Merzebany, Mahmoud ^a   Kilic, Gokhan ^b   Veenstra, Timothy ^c   Saeed, Muhammad ^d   Wagih, Mohamed ^e   Diaz Arrastia, Concepcion ^f   Patel, Deepa ^f   Salama, Salama ^f  

^a CAIRO UNIVERSITY   (Egypt)

^b University of Texas Medical Branch School of Medicine   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e Beni Suef University   (Egypt)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; DNA adducts; Estrogen metabo lizing genes and enzymes; Estrogen metabolites; Tumor necrosis factor alpha

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 4 HYDROXYESTRONE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; DNA; ESTRADIOL; ESTROGEN; ESTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE I; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA ADDUCT; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL REGULATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY MASS SPECTROMETRY; MASS SPECTROMETRY; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84875359965     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.4584     Document Type: Article

References (51)

1. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011; 61(6):409-18.
2. Henderson IC, Canellos GP. Cancer of the breast: the past decade. N Engl J Med. 1990; 302:17-30.
3. Henderson HS, Ross RK, Bernstein L. Estrogens as a cause of hu-man cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 1988; 48:246-53.
4. Russo j, Russo IH. Cellular basis of breast cancer susceptibility. Oncol Res. 1999; 11 (4):169-78.
5. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 1997; 2:323-334.
6. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG. Molecular origin of cancer: catechol estrogen- 3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94(20):10937-42.
7. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16 al-pha-hydroxylation of estradiol: a possible risk marker for breast cancer. Ann NY Acad Sci. 1986; 464:138-151.
8. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update. 2003; 6:355-361.
9. Cavalieri EL, Rogan EG. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol. 2011; 125(3-5):169-80.
10. Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007; 28:521-574.
11. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
12. Cole SW. Chronic inflammation and breast cancer recurrence. J Clin Oncol. 2009; 27(21):3418-9.
13. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009; 27(21):3437-44.
14. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 2006; 66(15):7395-400.
15. Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, Yull FE. Inhibition of NF-κB activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene. 2011; 30(12):1402-12.
16. Balkwill F. Tumor necrosis factor and cancer. Nat Rev Cancer. 2009; 9(5):361-71.
17. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Associa-tion of tumor necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer. 1988; 77:2246-2251.
18. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Expression of tumor necrosis factor (TNF-α) and its receptors in benign and malignant breast tissue. Int J Cancer. 1994; 56:777-782.
19. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Can-cer Res Treat. 1997; 43:211-215.
20. Balkwill F. Tumor necrosis factor or tumor promoting factor?. Cy-tokine Growth Factor. 2002; 13:135-141.
21. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI. Associa-tion of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004; 291:2433-2440.
22. Baumgarten SC, Frasor J. Inflammation: an instigator of more ag-gressive estrogen receptor ER-positive breast cancers. Mol Endo-crinol. 2012; 26(30):360-71.
23. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010; 11(9):1133-46.
24. Purohit A, Newman SP, Reed M. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 2002; 4(2):65-9.
25. Herrmann M, Scholmerich J, Straub RH. Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Ann NY Acad Sci. 2002; 966:166-186.
26. Hong CY, Park JH, Ahn RS, Im SY, Choi HS, Soh J, Mellon SH, Lee K. Molecular mechanism of suppression of testicular steroidogene-sis by proinflammatory cytokine tumor necrosis factor-alpha. Mol Cell Biol. 2004; 24:2593-2604.
27. Mikhaylova IV, Kuulasmaa T, Jaaskelainen J, Voutilainen R. Tumor necrosis factor-alpha regulates steroidogenesis, apoptosis, and cell viability in the human adrenocortical cell line NCI-H295R. Endo-crinol. 2007; 148:386-392.
28. Salama SA, Kamel MW, Diaz-Arrastia CR, Xu X, Veenstra TD, Salih S, Botting SK, Kumar R. Effect of TNF-α on estrogen metabolism and endometrial cells: potential physiological and pathological relevance. J Clin Endocrinol Metab. 2008; 94(1):285-93.
29. Xu X, Keefer LK, Ziegler RG, Veenstra TD. A liquid chromatog-raphy-mass spectrometry method for the quantitative analysis of urinary endogenous estrogen metabolites. Nat Protoc. 2007; 2(6):1350-5.
30. Zahid M, Gaikwad NW, Ali MF, Lu F, Saeed M, Yang L, Rogan EG, Cavalieri EL. Prevention of estrogen-DNA adducts formation in MCF-10F cells by resveratrol. Free Radic Biol Med. 2008; 45(2):136-45.
31. Zhang CY, Chen J, Yin DC, Lin SX. The contribution of 17beta-hydroxysteroid dehydrogenase type 1 to the estradi-ol-estrone ratio in estrogen-sensitive breast cancer cells. PLoS One. 2012; 7(1):e29835.
32. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. In-flammation and cancer: how hot is the link?. Biochem Pharmacol. 2006; 72(11):1605-21.
33. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F. Tumor necrosis factor-alpha deficient mice are re-sistant to skin carcinogenesis. Nature Med. 1999; 5(7):828-31.
34. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-κB functions as a tumor promoter in inflammation associated cancer. Nature. 2004; 431(7007):461-6.
35. Balkwill F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 2006; 25(3):409-416.
36. Sethi G, Sung B, Aggarwal BB. TNF: a master switch from inflam-mation to cancer. Front Biosci. 2008; 13:5094-107.
37. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010; 11(9):1133-46.
38. Macdiarmid F, Wang DY, Duncan LJ, Purohit A, Ghilchik MW, Reed MJ. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor- alpha. Molec Cell Endocr. 1994; 106:17-21.
39. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, Du B, Brogi E, Crawford CB, Kopelovich L, Subbaramaiah K, Dannen-berg AJ. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011; 4(7):1021-9.
40. Liehr JG, Ricci MJ. 4-hydroxylation of estrogens as markers of hu-man mammary tumors. PNAS. 1996; 93: 3294-3296.
41. Gharavi N, El-Kadi AO. Role of nitric oxide in downregulation of Cytochrome P-450 1A1 and NADPH Quinone oxidoreductase 1 by tumor necrosis factor-alpha and lipopolysaccharide. J Pharm Sci. 2007; 96(10):2795-807.
42. Tchivileva IE, Nackley AG, Qian L, Wentworth S, Conrad M, Diatchenko LB. Characterization of NF-κB-mediated inhibition of Catechol-O-methyltransferase. Mol Pain. 2009; 5:13.
43. Morel Y, Mermod N, Barouki R. An autoregulatory loop controlling CYP1A1 gene expres-sion: role of H2O2 and NFI. Mol Cell Biol. 1999; 19(10):6825-32.
44. Fussell KC, Udasin RG, Smith PJ, Gallo MA, Laskin JD. Catechol metabolites of endogenous estrogens induce redox cycling and generate reactive oxygen species in breast epithelial cells. Carcino-genesis. 2011; 32(8):1285-93.
45. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000; 19(1-2):173-9.
46. Rosenberg LU, Magnusson C, Lindström E, Wedrén S, Hall P, Dickman PW. Menopausal hormone therapy and other breastcancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res. 2006; 8(1):R11.
47. Cole P, MacMahon B. Estrogen fractions during early reproductive life in the etiology of breast cancer. Lancet. 1969; 1:604-606.
48. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen re-ceptor-negative breast cancer cells. Mol Cell Endocrinol. 2010; 320(1-2):162-70.
49. Mailander PC, Meza JL, Higginbotham S, Chakravarti D. Induction of AT to GC mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol. 2006; 101(4-5):204-15.
50. Naushad SM, Reddy CA, Rupasree Y, Pavani A, Digumarti RR, Gottumukkala SR, Kuppusamy P, Kutala VK. Cross-talk be-tween one-carbon metabolism and xenobiotic metabolism: implica-tions on oxidative DNA damage and susceptibility to breast cancer. Cell Biochem Biophys. 2011; 61(3):715-23.
51. Aggarwal BB, Ichikawa H. Molecular targets and anticancer poten-tial of indole-3-carbinol and its derivatives. Cell Cycle. 2005; 4(9):1201-15.